3/16/2023 | BKBWHYIGLM | Charles River Labs continues lowering leverage through debt repayment
|
6/21/2022 | BKHYIG | Fitch gives Charles River loan BBB, notes BBB-
|
1/11/2022 | BWHYLM | Charles River Labs lifts leverage target after M&As to 3.5x from 3x
|
4/23/2021 | BK | Charles River Labs gets $3 billion amended five-year revolver
|
3/9/2021 | BKCVDDEMIGPV | Market Commentary: Primary reasonably busy; secondary firms; Charles River gains; Alcoa in focus
|
3/9/2021 | HY | Market Commentary: Primary reasonably busy; secondary firms; Charles River gains; Alcoa in focus
|
3/8/2021 | HY | Market Commentary: Charles River, Alcoa price; forward calendar grows; Playtika holds; Twilio active
|
3/8/2021 | BKCVDDEMIGPV | Market Commentary: Charles River, Alcoa price; forward calendar grows; Playtika holds; Twilio active
|
3/8/2021 | HY | New Issue: Charles River prices $1 billion unsecured notes two tranches
|
3/8/2021 | BKHY | Moody's assigns Charles River notes Ba2
|
3/8/2021 | HY | Charles River driving by with $1 billion notes in eight-year and 10-year tranches
|
3/8/2021 | BKHY | S&P assigns Charles River notes BB
|
3/8/2021 | HYLM | Charles River Laboratories to redeem 5½% notes due 2026
|
2/17/2021 | BKBWHY | Charles River leverage to rise from purchase; debt markets considered
|
11/20/2020 | BKHY | Moody's upgrades Charles River
|
9/4/2020 | SP | New Issue: GS Finance sells $830,000 leveraged basket-linked notes on 103 stocks
|
2/11/2020 | BKBWHY | Charles River Labs aims for 3x leverage; debt reduction is a priority
|
12/16/2019 | BK | Charles River to use credit facility borrowings to purchase HemaCare
|
10/22/2019 | HY | New Issue: Charles River Laboratories prices $500 million 8.5-year notes at par to yield 4¼%
|
10/21/2019 | BKHY | Moody’s ups Charles River notes, rates new notes Ba3
|
10/21/2019 | BKHY | S&P assigns BB to Charles River bonds
|
10/21/2019 | HY | Charles River guiding $500 million notes due 2028 at 4½%-4¾% area
|
6/5/2019 | BKBWHYIG | Charles River Labs aims to keep leverage below 3x, but may go higher
|
5/1/2019 | BKCVHYIG | S&P lowers Charles River to junk
|
2/15/2019 | BK | S&P puts Charles River Labs on watch
|
2/14/2019 | BKCVHYIG | S&P puts Charles River on watch
|
4/10/2018 | HY | Market Commentary: Hilton, Silversea upsize; junk market strong; Sprint up on merger news; Tenneco down
|
4/10/2018 | BKCVDDEMIGPV | Market Commentary: Hilton, Silversea upsize; junk market strong; Sprint up on merger news; Tenneco down
|
3/29/2018 | BKCVDDEMIGPV | Market Commentary: Ply Gem, Wyndham, W/S price; McDermott delayed; recent deals mixed; funds off $0.62 billion
|
3/29/2018 | HY | Market Commentary: Ply Gem, Wyndham, W/S price; McDermott delayed; recent deals mixed; funds off $0.62 billion
|
3/28/2018 | BKCVDDEMIGPV | Market Commentary: Coty, Charles River price; McDermott widens talk; Tronox trades down; Tesla dominates
|
3/28/2018 | HY | Market Commentary: Coty, Charles River price; McDermott widens talk; Tronox trades down; Tesla dominates
|
3/28/2018 | HY | New Issue: Charles River Laboratories prices $500 million eight-year notes at par to yield 5½%
|
3/28/2018 | HY | Market Commentary: Morning Commentary: McDermott downsized, heard to be widening; Boyne bonds soar
|
3/26/2018 | BKHYIG | Moody’s ups Charles River loans, rates notes B1
|
3/26/2018 | BKHYIG | S&P rates Charles River notes BB+
|
3/26/2018 | BK | Charles River refinances credit facilities for upsized $2.3 billion
|
3/26/2018 | HY | Market Commentary: Morning Commentary: Busy pre-Easter calendar continues to build; new Cequel 7½% notes trading well
|
3/26/2018 | HY | Charles River Laboratories to sell $500 million eight-year notes during March 26 week
|
2/14/2018 | BK | S&P affirms Charles River
|
2/13/2018 | BK | Charles River gets $830 million bridge loan commitment via JPMorgan
|
4/5/2016 | BK | Charles River Labs gets $1.65 billion five-year term loan, revolver
|
1/12/2016 | BKIG | S&P affirms Charles River, loans
|
1/7/2016 | BK | Moody’s: Charles River to stable
|
7/9/2015 | BK | Charles River to draw from revolver for $212 million Celsis purchase
|
4/28/2015 | BKCV | Moody’s rates Charles River revolver, loan Ba2
|
4/24/2015 | BKIG | S&P: Charles River Laboratories facility BBB-
|
4/22/2015 | BK | Charles River restates credit facilities to cut pricing, amend maturity
|
3/13/2014 | BK | Charles River Laboratories to draw on euro revolver for acquisition
|
6/19/2013 | BKCV | Charles River: Q1 sales rise; refinanced credit agreement won't affect capital deployment, says CFO
|
6/11/2013 | BKCV | Moody's rates Charles River Laboratories amended loans Ba2
|
5/29/2013 | BK | Charles River enters into $970 million restated term loan, revolver
|
3/14/2013 | CV | Market Commentary: Suntech Power active at 30 as potential default looms; Charles River pops; Salesforce quiet around par
|
7/31/2012 | CVIGPF | Charles River Labs files automatic shelf for stock, preferreds, debt
|
2/21/2012 | BKCV | Moody's: Charles River to SGL-3
|
2/14/2012 | CV | Market Commentary: Convertibles weaken some; Gilead mixed; Charles River flat on earnings; DryShips jumps
|
12/14/2011 | BKCV | Charles River Labs cuts debt in 2011, targets up to $175 million of free cash flow for 2012
|
9/28/2011 | CV | S&P: Charles River unaffected
|
9/26/2011 | BKCV | Moody's rates Charles River loan Ba1
|
9/23/2011 | BK | Charles River Laboratories amends $750 million term loan, revolver
|
9/23/2011 | CV | Market Commentary: NuVasive seen as interesting story despite Medtronic issues; aircraft, airline space busy
|
4/6/2011 | CV | Market Commentary: Fifth Street intends to price $150 million notes; Amerigroup, SM Energy paper cheapening
|
2/24/2011 | BKCV | Moody's affirms Charles River
|
2/24/2011 | BKCV | S&P: Charles River loan BBB-
|
2/10/2011 | CV | Market Commentary: Charles River adds slightly on hedge; Energy Conversion higher; Molycorp upsizes, prices
|
8/31/2010 | BK | Charles River gets $750 million amended and restated credit facility
|
8/27/2010 | BKCV | Moody's rates Charles River loans Ba1
|
8/3/2010 | BKCV | Moody's drops Charles River Labs loan
|
7/30/2010 | BK | Market Commentary: Savvis, Ntelos break; Warner Chilcott dips; Calpine seesaws; Midcontinent sets spread, adds step
|
7/30/2010 | BKCV | Moody's: Charles River unaffected
|
6/14/2010 | CV | Market Commentary: Transocean fluctuates; Microsoft flat on hedged basis; Chesapeake Energy a little weaker
|
6/11/2010 | BK | Market Commentary: Wendy's firm on buyout buzz; Willbros changes expected; Sophos tranching, Telx spread set
|
6/10/2010 | BK | Charles River's $1 billion term A expected at Libor plus 275 bps
|
6/10/2010 | BK | Market Commentary: TransUnion tweaks deal, breaks; Citgo upsizes; Styron allocating soon; Guardian firms structure
|
6/4/2010 | BKCV | Moody's cuts Charles River, rates loans Ba1
|
6/4/2010 | BKCV | S&P affirms Charles River, rates loans BBB-
|
5/14/2010 | CV | Market Commentary: Remarketed Stanley in trade at 109; Charles River weaker in active trade; AMD, Intel quiet
|
4/27/2010 | BKCV | Moody's may cut Charles River Labs
|
4/26/2010 | BK | Charles River plans $1.25 billion credit facility for WuXi purchase
|
4/26/2010 | BKCV | S&P may cut Charles River
|
4/26/2010 | BKCV | S&P may cut Charles River
|
4/26/2010 | CV | Market Commentary: PMI bid up in gray market; Lennar gray bid tepid; M&A drives trade in Charles River, Hertz
|
12/21/2009 | BKCV | Moody's ups Charles River Labs loan
|
8/4/2009 | CVIG | Charles River files automatic shelf covering debt, preferreds, stock
|
4/23/2009 | BKCV | S&P: Charles River Labs view stable
|
3/12/2009 | BKCV | Moody's: Charles River view negative
|
8/11/2008 | BKCV | Moody's cuts Charles River to SGL-2
|
3/10/2008 | BKCV | Moody's ups Charles River outlook to stable
|
2/22/2008 | CVIG | S&P ups Charles River Labs from junk
|
11/8/2006 | BT | Charles River kept at hold by Jefferies
|
11/7/2006 | BT | Charles River Labs on hold by Jefferies
|
10/9/2006 | BT | Market Commentary: New River rises 61.5%, Shire up 16% on ADHD drug nod; Coley eyed; NeoPharm higher by 20%
|
9/29/2006 | BKHY | Moody's introduces new ratings
|
9/25/2006 | CV | Market Commentary: Sandisk slips on downgrade; Equity Residential, National Retail gain on rate play; Charles River up on vol
|
9/22/2006 | BT | Charles River awarded $111.6 million National Cancer Institute contract
|
8/11/2006 | BT | Charles River kept at hold by Jefferies
|
8/9/2006 | CV | Market Commentary: BRE, Digital Realty bright in the gray; Amkor mixed on delayed filing; Tanger, Retail Ventures plan deals
|
8/9/2006 | BTCVHY | Charles River Labs files automatic shelf registration
|
8/9/2006 | BT | Adams Respiratory kept at sector perform by RBC
|
8/2/2006 | BKBT | Charles River gets amended and restated credit facility
|
7/27/2006 | CV | Market Commentary: Omnicare withstands profit cut; Symantec rises with results; XM unmoved by loss; Weingarten plans deal
|
7/18/2006 | BT | Charles River Labs to sell portable endotoxin test
|
6/27/2006 | BT | Charles River on hold by Jefferies
|
6/19/2006 | BKBTCV | S&P assigns Charles River Laboratories convertibles BB-
|
6/13/2006 | CV | Market Commentary: Advanced Medical, Charles River, Nabors gain on volatility; Symantec flat on debut; Nektar drops outright
|
6/7/2006 | BT | Market Commentary: Antigenics up 11% on data; Discovery Labs dives 19%; Incyte up; VaxGen slides
|
6/7/2006 | CV | Market Commentary: Interpublic, Spansion, Charles River climb, Millipore struggles on debuts; Level 3 up in gray; L-3 gains
|
6/7/2006 | BTCV | New Issue: Charles River $300 million seven-year convertibles price within talk, at 2.25%, up 22.5%
|
6/6/2006 | BT | Market Commentary: Xenoport deal emerges; Human Genome up 4%; Anadys, Idenix drop on HGSI news; Onyx up
|
6/6/2006 | CV | Market Commentary: New deals seen as unexciting; Spansion structure seen as too long; Charles River, Millipore views mixed
|
6/6/2006 | BTCV | Charles River prices $300 million seven-year convertibles to yield 2.25%, up 22.5%
|
6/5/2006 | CV | Market Commentary: SanDisk gains outright on stock upgrade; Sepracor falls on probe; Interpublic plans unique deal
|
6/5/2006 | BTCV | Charles River Laboratories' $300 million of seven-year convertibles talked at 2%-2.5%, up 22.5%-27.5%
|
5/11/2006 | BT | Charles River Labs on hold by Jefferies
|
5/10/2006 | BKBT | S&P's Charles River Labs ratings unaffected
|
5/10/2006 | BT | Jefferies keeps Charles River at hold
|
5/9/2006 | BT | Kendle to buy Phase II-IV from Charles River
|
3/22/2006 | BT | Charles River Labs to create test for detection of murine norovirus infection in lab mice
|
2/28/2006 | BKBT | Moody's rates Charles River loans Ba1
|
2/13/2006 | BT | Jefferies puts Charles River at hold
|
2/9/2006 | BT | Charles River at hold by Jefferies
|
2/9/2006 | BT | Market Commentary: Acorda IPO on deck with cheaper talk; Serono up on Glaxo chatter; Amylin soars; Charles River rises
|
12/22/2005 | BKBT | Charles River amends, restates to layer in new term loans, revolvers
|
12/19/2005 | BT | Jefferies lowers Charles River price target to $46
|
12/15/2005 | BT | Charles River maintained by Jefferies at hold
|
10/31/2005 | BT | Jefferies lowers Charles River price target to $47.50
|
10/31/2005 | BT | Market Commentary: NeoPharma skyrockets on new CEO; Charles River Labs higher; Nabi, Indevus, Invitrogen up
|
10/28/2005 | BT | Jefferies maintains hold on Charles River
|
10/14/2005 | BT | Clinical trial demand makes early-stage biotech contract researchers look interesting, Jefferies says
|
9/9/2005 | BT | Charles River Labs cut by Jefferies to hold
|
8/11/2005 | BKBTCV | S&P ups Charles River view to positive
|
7/29/2005 | BT | Charles River kept by Jefferies at buy
|
3/28/2005 | CV | Charles River Labs calls $185 million 3.5% convertibles
|
9/14/2004 | BKCV | Moody's rates Charles River loans Ba1
|
7/1/2004 | BK | Charles River $500 million credit facility to come via JPMorgan, CSFB
|
7/1/2004 | CV | S&P: Charles River Labs unaffected
|
2/26/2003 | BK | Moody's raises Alpharma outlook
|
2/26/2003 | CV | Moody's ups Alpharma outlook
|
2/26/2003 | HY | Moody's upgrades Chesapeake, rates notes Ba3, converts B3
|
2/13/2002 | HY | Tenders
|
1/30/2002 | HY | Tenders
|
1/18/2002 | CV | Market Commentary: Convertibles retreat, healthcare issues hit hard, Tyco takes wild ride
|
1/17/2002 | CV | New Issue: Charles River Labs upsized $175 million convertibles at 3.5%, up 30%
|
1/17/2002 | CV | Market Commentary: Convertibles rebound in frantic session of earnings news, Ford deal getting launched
|
1/17/2002 | HY | Tenders
|
1/16/2002 | CV | Market Commentary: Convertibles plunge with stock in hectic session, but new deals keep coming
|
1/16/2002 | HY | Moody's downgrades Kmart two notches, still on review
|
1/16/2002 | CV | Moody's downgrades Kmart two notches, still on review
|
1/15/2002 | CV | Charles River Labs $150 million convertibles talked 3.5-4.0% yield, up 24-28%
|
1/15/2002 | CV | Market Commentary: Convertibles flat, dull outside of new deal activity
|
12/11/2001 | HY | S&P cuts Dana to junk
|